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Abstract
Background: The enzymatic replacement therapy (ERT) availability for Gaucher disease (GD) has changed the
landscape of the disease, several countries have screening programs. These actions have promoted the early diagnosis
and avoided many complications in pediatric patients. In Spain ERT has been available since 1993 and 386 patients
have been included in the Spanish Registry of Gaucher Disease (SpRGD). The aim of this study is to analyze the impact
of ERT on the characteristics at time of diagnosis and initial complications in pediatric Gaucher disease patients.
Aim: To analyze the impact of ERT on the characteristics at time of diagnosis and initial complications in pediatric
Gaucher disease patients.
Methods: A review of data in SpRGD from patients’ diagnosed before 18 years old was performed. The cohort was
split according the year of diagnosis (≤1994, cohort A; ≥1995, cohort B).
Results: A total of 98 pediatric patients were included, GD1: 80, GD3: 18; mean age: 7.2 (0.17–16.5) years, 58 (59.2%)
males and 40 (40.8%) females. Forty-five were diagnosed≤ 1994 and 53≥ 1995. Genotype: N370S/N370S: 2 (2.0%),
N370S/L444P: 27 (27.5%), N370S/other: 47 (48%), L444P/L444P: 7 (7.1%), L444P/D409H: 2 (2.0%), L444P/other: 3 (6.2%),
other/other: 10 (10.2%). The mean age at diagnosis was earlier in patients diagnosed after 1995 (p < 0.001) and different
between the subtypes, GD1: 8.2 (0.2–16.5) years and GD3: 2.8 (0.17–10.2) years (p < 0.001). There were more severe
patients in the group diagnosed before 1994 (p = 0.045) carrying L444P (2), D409H (2), G377S (1), G195W (1) or the
recombinant mutation. The patients’ diagnosed ≤1994 showed worse cytopenias, higher chance of bone vascular
complications at diagnosis and previous spleen removal. The patients started ERT at a median time after
diagnosis of 5.2 years [cohort A] and 1.6 years [cohort B] (p < 0.001).
Conclusions: The early diagnosis of Gaucher disease in the era of ERT availability has permitted to reduce
the incidence of severe and irreversible initial complication in pediatric patients, and this has permitted better
development of these patients. This is the largest pediatric cohort from a national registry.
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Background
Gaucher Disease (GD)(OMIM#230800), the most com-
mon inherited lysosomal storage disorder is an auto-
somal recessively disease; the cause is mutations of the
beta-acid-glucosidase gene located in chromosome 1 in
the q21 region [1]. The gene alteration leads to a partial
or total lack of glucocerebrosidase (GBA) enzymatic ac-
tivity in the lysosome, GBA is a hydrolase responsible
for the degradation of the glycosphingolipid complex
glucosylceramide; the deficiency leads to an accumula-
tion of complex molecules of glucosylceramide inside
the lysosomes of reticuloendotelial cells, especially in
viscera and bone [2–4].
Clinically, there are 3 sub-types according to neuro-
logical involvement. Type 1 GD non-neuronopathyc GD
is the most common form of presentation in western
countries, and as the name indicates there are no neuro-
logical manifestations, type 3 is the second most fre-
quent and the clinical course is characterized by
neurological manifestations like ataxia, saccadic eye
movements, seizures and neurological impairment, and
non-neurological features like heart valves infiltration,
kyphosis and other characteristics described elsewhere
[5, 6], type 2 GD or acute neuronopathic form is the
most aggressive presentation of the GD, with severe
neurological impairment early in life (newborns to 1 year
old) with a short lifespan, usually around 2 years of age
[6–8]. Pathophysiology studies reveal that these three
types are a continuum of manifestations; from the more
severe, the type 2 form, followed by the intermediate dis-
ease of type 3 to milder or non-symptomatic phenotypes
of some type 1 patients [9, 10]. These multi-system man-
ifestations are based on the grade of residual GBA en-
zymatic activity, and the association of some mutations
with a high risk of neurologic-involvement [11, 12].
The time of diagnosis in GD is variable and directly
related to the rate of substrate accumulation and severity
presentation [13]. The clinical characteristics of pediatric
GD patients are growth retardation, nasal hemorrhages,
cytopenias, spleen enlargement and early bone crisis
prior to the era of enzyme replacement therapy (ERT)
the spleen was frequently removed to improve
hematologic parameters, but had a negative impact on
bone [14].
After more than two decades of ERT, few reports and
guidelines have highlighted the efficacy of an optimal ap-
proach to early institution of ERT in pediatric GD pa-
tients. The large studies are supported by statistics
extrapolating modelling-based studies from data from
the International Collaborative Gaucher Group Registry
(ICGGR) [15, 16] and several works from national co-
operative groups that have summarize information from
different cohorts [17–21]. However, the disease manifes-
tations are impacted by the ethnicity/population
characteristics and it is important to analyze what we
have achieved in every-day clinical practice with current
treatment and how the behavior of the disease has chan-
ged in the pediatric population, especially in children
treated from the first years of life. Focusing on that, a
country-based analysis from the Spanish Registry of
Gaucher Disease had been performed and presented
here.
Methods
Spanish registry
Since the establishment of the Spanish Registry of
Gaucher Disease (SpRGD) coordinated by the “Funda-
cion Española para el Estudio y Terapeutica de la
Enfermedad de Gaucher”, (FEETEG), a total of 386 GD
patients have been reported in Spain (www.feeteg.org).
All of them, or their parents in pediatric cases, had
signed informed consent to be part of the registry and
permit the use of their data. Approval from the ethics
committee and institutional boards were obtained and
all aspects are in accordance with the current version of
the Helsinki Declaration; the management of the pa-
tients was the responsibility of the local physician in
charge. From the FEETEG and GD unit, it is encouraged
to follow the actual international and European Working
Group on Gaucher Disease (EWGGD) recommendations
guidelines [22–25] and to perform at least one visit to
the GD unit for a general assessment.
Inclusion criteria
A retrospective review of the available data from patients
diagnosed in pediatric age (<18 years) and registered in
the SpRGD-FEETEG was performed. All patients had a
confirmed diagnosis of GD by determination of enzym-
atic activity B-acid glucosidase activity according to a
protocol based on the artificial substrate incubation with
4 methylumbelliferyl-B-D-glucoside-sonicated extracts
leukocyte [26], and identification of genetic mutations
by sequencing of GBA gene [27]. All biological samples
are kept in the Aragon Biobank and included in the
Lysosomal Collection. The analyzed variables were: gen-
eral demographic information, clinical manifestations,
biomarkers, visceral & bone involvement, genotype,
therapy and follow-up information. Period of study: May
1993 to April 2016.
Study variables
Year of diagnosis
The cohort was split into 2 subgroups according to
the diagnosis made before/in 1994 and after 1994.
This decision was taken considering that in 1993, in
the Miguel Servet University Hospital, the first adult
patient started therapy in Spain. This milestone was
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followed by many efforts to improve the diagnosis
and management of GD patients.
Hematologic values
Considering anemia, the hemoglobin levels (Hb) were
defined according to international values (WHO) of nor-
mal for age and gender: birth to 6 months, <10.1 g/dL;
6 months to 2 years, <9.5 g/dL; 2 years to 12 years,
<10.5 g/dL; more than 12 years, male, <12 g/dL and fe-
male, <11 g/dL.
For platelet counts, the normal value was considered
above 120 × 109 per L.
Visceral assessment
Liver and spleen volumes were assessed by physical
examination and, when available, also for ultrasound and
magnetic resonance. Considering the difficulty in sum-
marizing data, the information was recorded as cm bel-
low low marginal costal or as multiples of normal (MN)
size when a MRI was carried out.
Biomarkers studies
At diagnosis and for monitoring of patients chitotrio-
sidase activity and the chemokine-C-motif ligand 18/
Pulmonary-activation-regulated chemokine (CCL18/
PARC) are part of our standard care. In addition we
include the genotype of chitotriosidase to determine
the presence of the duplication of 24 pair of bases in
the 6th exon. The studies were done in plasma as
previously described [28, 29].
Bone disease assessment: For bone disease evaluation,
the history of chronic bone pain, bone crisis, bone le-
sions or deformities, and bone evaluations by X-ray or
MRI prior to starting ERT were noted.
Bone crisis was defined according to the clinical cri-
teria previously described [15], as “pain with acute onset
that requires immobilization of the affected area and
narcotics for the relief of pain and that may be accom-
panied by periosteal elevation, elevated white blood cell
count, fever, or debilitation that lasts longer than 3 days.”
Many were reported as suspected crisis and were regis-
tered according to the date the physician reported the
event as occurring.
For bone mineral density, the results from the densi-
tometry studies dual X-ray absorptiometry (DXA) or
ultrasound quantification by broadband ultrasound at-
tenuation (BUA) performed during routine follow-up
were included.
Disease severity evaluation
For this purpose, the Pediatric Gaucher Severity Scoring
system (PGS3) previously described by Kallisch S and
Kaplan P. was applied [30].
Statistical analysis
All the data were collected into a database and analyzed
using the SPSS v18.0 program. Because this is a national
data registry, many patients were not initially assessed in
our clinic, however from each patient, clinical and la-
boratory data were collected through the physician re-
ports so there was no need to perform any modeling
approach.
Results
Demographic characteristics
From the total of 386 patients diagnosed with Gaucher
Disease in Spain, 124 (32.1%) were diagnosed bellow
18 years, 26 (20.9%) were type 2 and the other 98
(79.1%) suspected to have type 1 disease, of these, 18
(14.5%) had a genotype other than N370S, developed
neurological symptoms and were re-classified as type 3.
For this work we considered only GD1 and GD3 pa-
tients, (n = 98). There was male predominance (58,
59,2%). The mean age at diagnosis was 7.2 years (range.
0.2–16.5), about half of the patients (48, 46.9%) were di-
agnosed at 5 years or less. The majority of patients 86
(87.8%) had features of GD, and the diagnosis were
established in the others (12, 12.9%) when family screen-
ing was performed.
A total of 45 (45.9%) patients were diagnosis during or
before 1994 and 53 (54.1%) after 1994. Regarding GD3
patients 13/18 were diagnosed after 1994 Fig. 1. In the
first 5 years of the ERT era 22 pediatric patients were di-
agnosed 4 had GD3. Table 1 summarizes more general
characteristics and compares them with the time of
diagnosis.
Genotyping & GD subtypes
In mutational analysis N370S compound heterozygosis
(73, 74.5%) was the most frequent genotype, of which
N370S/L444P was the most common (26, 26.5%). Only
2 (2.0%) patients were homozygous for N370S. Regard-
ing the GD3 patients, homozygosity for L444P was the
most frequent genotype (7/18, 41.0%) See Fig. 2.
In general, majority of patients (70.4%, 69 cases) car-
ried at least one severe mutation (L444P, D409H, RecNi,
84GG, W(−4X), T391P, del55pb, G202R, G195W,
P182L, E326K and others). In 20.4% (20) the severity of
the mutation was unknown and the remainder were
mild (N370S, G377S), (data not shown) [12].
Baseline evaluation
During diagnosis or follow-up process 17 patients were
splenectomized, three underwent a liver biopsy. There
was an association (p < 0.001) between the diagnosis be-
fore 1994 and splenectomy (14/17 cases), the last three
spleen removals occurs in 1998–2001 during the diag-
nostic process.
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According to the PGS3, in GD1 patients (n = 80), more
than half had mild disease at baseline (41, 56.3%), 19
(26.0%) had moderate and 13 (17.8%) had severe presen-
tations, there were incomplete data in seven cases.
When the PGS3 was applied to GD3 patients 10 (62.3%)
was classified as mild, five (31.3%) as moderate and 1
(6.3%) as severe. “There were more severe patients in
the group diagnosed before 1994 (p = 0.045).
Visceral involvement
Splenomegaly affected all patients; the mean for cohort
A was 9.8 (2–23) cm below costal rib (BCR) and for co-
hort B 7.7 (3–19) cm BCR. Hepatomegaly was more
prevalent in cohort A.
Hematologic involvement
Table 1 details the hematological parameters at baseline
and compares the values in the two cohorts. In cohort
A, 86.7% (30, missing data = 9) of patients at diagnosis
showed anemia and/or thrombocytopenia, with a mean
Hb value of 9.1 (8.0–10.5) g/dL and platelet count of
80.9 (21–112) ×109/L, cohort B showed 66.7% (30 cases,
6 missing data) with a mean Hb concentration of 9.7
(6.9–10.9) g/dL and platelets count of 89.3 (44–117)
×109/L. The presence of thrombocytopenia was higher
in cohort A (p < 0.001) and had lower values (p = 0.02)
(89.3 vs 128 × 109/L).
Bone disease
There were clear differences between both cohorts (p <
0.001), with more severe disease presentation in cohort
A. This was associated with a mean older age at diagno-
sis for cohort A, 9.0 (0.5–16.5) years, and for cohort B,
5.7 (0.2–15.9) years (p < 0.001), an undoubted improve-
ment after therapy availability. In the A cohort, a total of
21 (50%) patients reported bone pain before diagnosis,
16 had reported symptoms that resembled a bone crisis
and two patients had suffered vertebral fractures. In the
cohort B only 12 (26.7%) reported bone pain at diagnosis
and seven reported a bone crisis or/and AVN (4). Two
L444P homozygous patients developed Norbottnian-like
thoracic deformations before 10 years of age and this
was reported during the diagnosis process. There was no
correlation between the presentation of bone symptom-
atology and early diagnosis, however the hazard ratio
(HR) to manifest a bone complications was 1.7 times
higher in cohort A compared to Cohort B with statisti-
cally significant (p = 0.025) differences between them.
Osteopenia
In 13 patients form cohort A osteopenia was assessed
and found 5 (38.5%) patients at diagnosis and in cohort
B 6/16 (37.5%) assessed patients had osteopenia at diag-
nosis, there were no differences between the two co-
horts. Probably the incidence of osteopenia is under
diagnosed due to un-availability of densitometry in all
the centers.
Biomarkers
All the patients showed abnormal values of chitotriosi-
dase, except one with homozygous 24 pb duplication in
the CHIT1 gene with 0 activity; 11 patients were
Fig. 1 Timeline of pediatric diagnosed cases
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heterozygous for 24 pb duplication in CHIT1 gene. The
mean values for chitotriosidase showed a wide distribu-
tion ranging from 1,123 to 65,497 nmol/mgprot.h. For
the cytokine CCL18/PARK all the assessed patients
showed high abnormal values ranging from 151 to
3,763 ng/mL. The observed differences between cohorts
about the biomarkers values were no statically
significant.
Growth assessment
Eight patients (5 from cohort B) were below the ten per-
centile for height and gender at diagnosis. There were
no significant differences regarding the availability of
data to calculate the expected height according parents
heights, and there were scanty data from the cohort A
patients to establish a proper correlation. From the co-
hort B, all patients achieved a normal weight and im-
prove the percentile for height to normal patterns
during therapy.
GD1 patients (n = 80)
Each cohort included 40 GD1 patients with only one
N370S homozygous patient in each one and a similar
frequency of N370S/L444P patients (Cohort A 13,
32.45% patients, Cohort B 14, 35.0% patients), the most
common genotype in our population. Based on mutation
analysis performed by our group few years ago [11, 12],
the majority of patients (33 and 25 cases in cohort A
and B respectively) carried an allele with mutations cate-
gorized as severe, i.e. 84GG, del55pb and other null
Table 1 General characteristics comparison according cohorts
Baseline characteristic Cohort A N = 45 (%)(Dx ≤1994) Cohort B N = 53 (%)(Dx≥ 1995) Total (n = 98) N (%) Diff.
Gender M/F (%) 27/18 (60/40) 31/22 (58.5/41.5) 58/40 (59.2/48.8) NS
Age at Dx (years) 9.0 (05–16.5) 5.7 (0.2–15.9) 7.2 (0.2–16.5) p < 0.001
Patient/sibling (%) 39/6 (86.7/13.3) 47/6 (88.7/11.3) 86/12 (87.7/12.3) NS
GD1/GD3 40/5 (88.9%/11.1%) 40/13 (75.5%/24.5%) 80/18 (81.6/18.4) NS
Pediatric Gaucher Severity Index score
Mild 22 (53.7) 29 (60.4) 51 (52.0) NS
Moderate 7 (17.1) 17 (35.4) 24 (24.5) NS
Severe 12 (29.3) 2 (4.2) 14 (14.3) P = 0.045
Symptoms and signs at diagnosis
Splenomegaly 45 (100) 47 (88.6) 92 (93.9) NS
Hepatomegaly 27* (60%) 40 (75.5) 67 (68.4) p = 793
Splenectomy 15 (39.5%) 4 (7.8) 19 (19.4) p < 0.001
Anemia or thrombocytopenia 30 (83.3%) 30 (66.7) 60 (61.2) p = 0.047
Mean Hb (range) g/dL 11.4 (8.0–14.7) 11.3 (6.9–13.8) 11.4 (6.9–14.7) NS
Mean Platelets count (range) 89.3 (21–200) × 109/L 128.3 (44–363) × 109/L 112.9 (21–363) p < 0.001
Other characteristics & biomarkers
Bone symptomatology 21 (50) (3missing) 12 (26.7) (8 missing) 33 (37.9, 11 missing) p < 0.001
Bone pain (only) 5 (11.9) 3 (6.7) 8 (9.2) NS
Vascular bone complication 16 (38.1%) 9 (20.0) 25 (25.5) p = 0.025
Chitotriosidase 17,277 (1,123–65,497) 11,038 (370–38,882) 12,437 (370–65497) NS
CCL18/PARC 271 (151–552) 1,273 (105–3763) 1,023 (105–3,763) NS
Genotypes GD1
N370S/N370S 1 (2.2) 1 (1.9) 2 (2.0) NS
N370S/L444P 13 (28.9) 14 (26.4) 27 (27.5) NS
N370S/Other 25 (55.6) 22 (41.5) 47 (47.9) NS
Other/Other 1 (2.2) 3 (6.7) 4 (4.08)
Genotypes GD 3
L444P/L444P 0 (0) 7 (13.2) 7 (7.1) -
L444P/Other 3 (6.7) 2 (3.8) 5 (5.1) NS
Other/Other 2 (4.4) 4 (7.5) 6 (6.12) NS
Dx diagnosis, pts patients
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mutations, combined mutations, G195W, G202R, T134P
and others (data not published in this article). Regarding
the initial symptoms, bone pain was the chief complaint
in 20 (50%) of GD1 patients of cohort A while in Cohort
B, spleen enlargement was the most common sign and
only 12 (30%) GD1 patients reported bone pain in co-
hort B as was previously described.
GD3 patients (n = 18)
Five patients from cohort A were GD3, none of them
L444P homozygous, but carrying L444P (2), D409H (2),
G377S (1), G195W (1) or the recombinant mutation
E326K +N188S (2) with other mutations. In cohort B,
13 patients were GD3, 7 homozygous L444P, 1 L444P
with another mutation and 5 with other mutations:
homozygous D409H (1), heterozygous D409H (3), RecNi
(2), homozygous P266L, heterozygous R463C (1) or
G377S (1).
The initial manifestation of GD3 phenotype were stra-
bismus/oculomotor apraxia in 11, psychomotor retard-
ation in 3, myoclonic epilepsy in 3 and thorax in bunker
was present in 2 L444P homozygous patients (one of
them with saccadic eyes movement).
From the patients whom access to therapy after child-
hood, in cohort A (31 cases).
ERT access
The median follow-up (until last contact or 18 years old)
was 8.8 (0.3–17.5) years. During this time 12 patients
(26.7%) of cohort A and 42 (79.2%) from cohort B initi-
ated ERT during childhood, (p < 0.001), globally 55.1%
(54) of cases. The mean global time from diagnosis to
ERT for cohort A was: 5.2 (0.1–11.9) years, and for co-
hort B: 1.6 (0.1–11.2) years (p = 0.001). The mean age at
ERT for cohort A was 12.2 (2.9–17.1) years and for co-
hort B: 6.6 (0.2–16.0) years, (p = 0.001).
From the patients whom access to therapy after child-
hood, in cohort A (31 cases, missing data 2 cases), the
mean age was 31.1 (18.4–45.9) years and for cohort B
there was only one case (missing data, 11 cases) at
18.1 years.
Discussion
Besides Ashkenazy’s Jewish people, GD is a panethnic
and rare disease with a prevalence around 1/70,000–
100,000 population [6]. In Spain, the Spanish Registry of
Gaucher Disease, has reported 386 patients since the es-
tablishment of the registry in 1993 for an updated preva-
lence of ~ 1:117,000 habitants (www.feeteg.org, updated
in May 2016).
At the time the diagnostic process was started by pedia-
tricians, family medicine or other specialists, the main
manifestations included alterations in blood counts and
spleen enlargement; this generally required a hematological
consultation, that led to the diagnosis in approximately
75% of GD patients [31, 32]. In our experience the clinical
suspicion based on the presence of organomegaly, an-
aemia, thrombocytopenia and bone pain had been suffi-
cient to identify the majority of patients, thus avoiding
bone marrow aspiration/biopsy.
Around 49% of the cases (reported from the inter-
national GD registry, ICCG) are diagnosed before
Fig. 2 Genotype Distribution
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10 years of age and 66% before 20 years old [15]. Prob-
ably an early diagnosis suggests a more aggressive behav-
ior of the disease; in our experience, thanks to the
efforts of the FEETEG collaborators, only 34.0% of chil-
dren with GD were diagnosed after 10 years, and 38.1%
were diagnosed before 5 years, an important improve-
ment compared to the international experience. When
these data are analyzed regarding the availability or not
of therapy, after 1994, 75% of diagnosed patients were
bellow 10 years of age and 53.8% bellow 5 years of age, a
clear improvement compared to the international ex-
perience. However this sub-analysis has not been made
with the ICGG Registry data so cannot be compared.
The availability of enzymatic replacement therapy has
changed the landscape of Gaucher disease pediatric pa-
tients; the starting point was the worldwide introduction
in 1991 of Ceredase (Genzyme, Cambridge, USA) and its
replacement by the recombinant form imiglucerase
(Cerezyme, Genzyme, Cambrigde, USA) in 1994. It took
more than 15 years to add two new enzymes to the
therapeutic arsenal, velaglucerase alfa (VPRIV, Shire,
Cambrigde, USA), identical to the human enzyme, ap-
proved in 2010 and taliglucerase alfa (Protalix, Carmel,
Israel) the first plant-based enzyme form approved in
2012. The oral substrate reduction therapy is not yet an
option for pediatric patients. Enzyme replacement ther-
apy (ERT) is a non-curative and expensive therapy, is ef-
fective in alleviating the visceral manifestations,
decreasing bone marrow burden(BMB)/infiltration and
preventing bone crisis and bone lesions [33, 34].
Despite the availability of ERT, the key diagnosis
features of type 1 Gaucher Disease (GD1) are still the
hematologic alterations like low hemoglobin concen-
tration, low platelet count, bone pain/bone crisis,
hepato- and splenomegaly [32]. Splenomegaly was al-
most universal in our pediatric patients presentation,
66.7–83.3% presented with hematologic alterations
and 26.7–50% with bone manifestations. This is con-
sistent with other reports including the ICGG Registry
[13, 30, 33] and a call for increased awareness in the
hematologic field to identified these patients.
The goals of therapy by Pastores et al. [22] are based
on the improvements achieved by at least 80% of the pa-
tients treated with enzymatic replacement therapy and
this needs to be optimized according the different pres-
entation of the patients. Working with rare disease is a
continual challenge, and more in a pediatric setting, the
initial problem is, in our experience, to spread widely
the knowledge to physicians to recognize the disease
and to carry out an extensive baseline assessment to
identified the patients in need of therapy and thus avoid
complications [35]. Pediatric patients usually reflect
more physiologic alterations, with high risk for bone dis-
ease and chronic growth failure [15]. The current
recommendations for start ERT on children [22], are
based in the presence of symptomatology, growth ten-
dency, bone, visceral and hematological alterations. In
patients with severe genotypes such L444P and D409H
or other genotypes that suggest the diagnosis of a GD3
case, is recommended to initiate therapy as soon as pos-
sible. For asymptomatic patients diagnosed bellow
20 years old, it is recommended to start ERT if they are
sibling of a patient who requires therapy.
In this respect, it should not be forgotten that the
prevalence of genotypes varies among the different pop-
ulations; in Ashkenazi Jews, N370S is the most frequent
mutation [36] and more than the 40% of those pediatric
patients are homozygous for N370S mutation [37], a rare
feature in our population (only 2 cases, 2.0%). In our co-
hort there was a predominance of L444P compound het-
erozygotes and other severe mutations, in line with the
more aggressive phenotypes. The data from the inter-
national Gaucher Registry also show a lower frequency
of N370S/L444P genotype than in our population
(14.8%) and a higher presence of N370S in homozygosity
(7.9%) [15]. This shows the necessity to establish local
recommendations based on population characteristics.
In respect to bone crisis, data from the IGGC registry
report only 17% of patients with bone crisis [15], from
the UK registry study 26% GD1 patients reported bone
pain [17], but in our cohort, bone alterations were
present in 37.9% (33) of cases, with a clear predomin-
ance (50%, 21 cases) in the cohort diagnosed before
1994 than the patients diagnosed after ERT became
available. This is a clear feature of a more severe presen-
tation in our country.
Conclusions
According to the data including in the Spanish Gaucher
Disease Registry the mean age at diagnosis in childhood
has changed from 9.0 to 5.7 years in the last 21 years.
In the Spanish population there is greater tendency to
severe phenotypes and genotypes in pediatric population
compared with ICGGR, probably related to the different
genotype spectrum. In our cohort, excluding the sib-
lings, the patients were symptomatic and following the
current recommendation in need of therapy. The indica-
tions for therapy based on the presence of severe
mutations have to be considered according the local
spectrum of mutations and behavior of patients. The
presence of infrequent mutations like R463C, G377S,
P266L and recombinant alleles need to be considered
among the indicators for therapy.
Related to bone disease, the higher prevalence of bone
complications in children with delayed start of therapy is
remarkable, in our study 1.7 times higher in children di-
agnosed before 1994.
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Comparing the patients diagnosed before or after the
availability of ERT this aspect has improved. Physicians
need to be careful and recognize patients with less se-
vere manifestation in order to initiate therapy early and
avoid the disease complications. These changes are re-
lated with the increased awareness of physicians and the
efforts made to diagnose patients after ERT became
available.
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